Literature DB >> 2773786

Comparison of nifedipine, propranolol and isosorbide dinitrate on angiographic progression and regression of coronary arterial narrowings in angina pectoris.

A Loaldi1, A Polese, P Montorsi, N De Cesare, F Fabbiocchi, P Ravagnani, M D Guazzi.   

Abstract

Calcium antagonists and beta blockers may retard or inhibit atherogenesis. This study investigated whether nifedipine or propranolol influences coronary atherosclerosis in humans. In selected patients with effort angina and proven coronary artery disease, the cineangiographic pattern after 2-year therapy with nifedipine (group 1, 39 patients), propranolol (group 2, 36 patients) or isosorbide dinitrate (group 3, 38 patients) was compared to that before treatment. The disease evolved to a different extent in the 3 groups. Patients with evidence of progression of old narrowings and appearance of new narrowings were significantly fewer in group 1 (31% and 10%) than in group 2 (53% and 34%) and group 3 (47% and 29%). The number of stenoses with evidence of progression was significantly smaller after nifedipine (14), and larger after propranolol (39) compared with group 3 (24). Thus, nifedipine seemed more protective than the other 2 drugs against coronary atherosclerosis. The coronary risk factors were normal in the nifedipine group and remained so with treatment, suggesting that they were dissociated from influences on atherosclerosis. The evolution, as judged by the number of narrowings with progression, appeared significantly (p less than 0.01) worse with propranolol than with isosorbide dinitrate. Propranolol caused unfavorable modifications of serum lipids; there was a 28% increase in total triglycerides and a 25% decrease in high density lipoprotein cholesterol at 12 months in group 2.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2773786     DOI: 10.1016/0002-9149(89)90417-7

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  19 in total

Review 1.  Atherosclerosis: inhibition of regression as therapeutic possibilities.

Authors:  M J Davies; D M Krikler; D Katz
Journal:  Br Heart J       Date:  1991-06

2.  Drug Treatment of Hypertension: Controlling elevated blood pressure.

Authors:  D R Ryan
Journal:  Can Fam Physician       Date:  1991-03       Impact factor: 3.275

3.  Calcium-channel blockers inhibit human low-density lipoprotein oxidation by oxygen radicals.

Authors:  C Napoli; M Chiariello; G Palumbo; G Ambrosio
Journal:  Cardiovasc Drugs Ther       Date:  1996-09       Impact factor: 3.727

Review 4.  Age-related changes affecting atherosclerotic risk. Potential for pharmacological intervention.

Authors:  L G Spagnoli; A Mauriello; A Orlandi; G Sangiorgi; E Bonanno
Journal:  Drugs Aging       Date:  1996-04       Impact factor: 3.923

5.  An antioxidant role for calcium antagonists in the prevention of adrenaline mediated myocardial and endothelial damage.

Authors:  A A Noronha-Dutra; E M Steen-Dutra; N Woolf
Journal:  Br Heart J       Date:  1991-06

Review 6.  Modification of atherosclerosis by agents that do not lower cholesterol.

Authors:  J G Cleland; D M Krikler
Journal:  Br Heart J       Date:  1993-01

7.  Quantitative angiographic follow-up studies on the development of coronary artery disease: which coronary segments should be analyzed? Experience from INTACT.

Authors:  S Jost; J Deckers; W Rafflenbeul; J H Reiber; P Nikutta; B Wiese; H Hecker; P Lippolt; M Riedel; C W Nolte
Journal:  Int J Card Imaging       Date:  1993-03

Review 8.  Radiographically detectable calcium and atherosclerosis: the connection and its exploitation.

Authors:  R Detrano; S Molloi
Journal:  Int J Card Imaging       Date:  1992

9.  Use of cell culture for optimisation of direct antiatherogenic therapy with verapamil.

Authors:  A N Orekhov; E M Pivovarova; I A Sobenin; V V Yakushkin; V V Tertov
Journal:  Drugs       Date:  1992       Impact factor: 9.546

Review 10.  Secondary and tertiary prevention with calcium antagonists in coronary artery disease.

Authors:  F Burkart
Journal:  Drugs       Date:  1992       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.